Selectis Health (GBCS) EBITDA (2010 - 2025)

Selectis Health has disclosed EBITDA across 16 years of filings, most recently posting -$395676.0 for Q4 2025.

• EBITDA for Q4 2025 came in at -$395676.0, down 118.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$474210.0 (down 167.92% YoY), and the FY2025 annual result was -$1.6 million, down 207.38% from the prior year.
• EBITDA came in at -$395676.0 for Q4 2025 at Selectis Health, down from $67739.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.1 million in Q4 2024 to a low of -$2.6 million in Q4 2023.
• The 5-year median for EBITDA is -$180106.0 (2024), against an average of -$204514.4.
• Across the five-year window, EBITDA soared 85648.96% in 2022 and slumped 1665.41% in 2023, its largest moves.
• Selectis Health's EBITDA stood at -$715292.0 in 2021, then slumped by 38.18% to -$988381.0 in 2022, then slumped by 159.27% to -$2.6 million in 2023, then jumped by 182.84% to $2.1 million in 2024, then slumped by 118.64% to -$395676.0 in 2025.
• The last three EBITDA figures came in at -$395676.0 (Q4 2025), $67739.0 (Q3 2025), and -$87547.0 (Q2 2025), per Business Quant data.